Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Shares rose 37% over 21 trading days and broke above the prior $28.01 high on above-average volume. Revenue grew 45% to $263.7 million, 2026 guidance was raised, and the nationwide Caris Detect rollout adds a recent catalyst.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Margin Improvement ⢠Strong Liquidity ⢠Dilution Risk CAI shows improving margins and strong liquidity, but persistent losses, rising leverage, dilution, weak cash deployment, and elevated valuation warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Strong upside momentum ⢠$31 resistance ⢠Pullback risk Support Level: $28.20â$28.50 Resistance Level: $31.00 CAI is bullish over the last month but faces $31.00 resistance and elevated pullback risk unless it holds above $28.20.
Sentiment & News
Key News Insights: ⢠AI Treatment Research ⢠Lung Cancer Studies ⢠Detect Campaign Launch Caris Life Sciences advanced its precision-oncology pipeline, AI-guided treatment research, and national blood-test marketing, though adoption costs and earnings revisions may temper near-term upside.
AI Summary
CAI's upside now hinges less on its proven molecular-profiling growth and more on whether Caris Detect and AI-enabled oncology tools achieve reimbursed, scalable adoption before commercialization spending, leverage, and dilution erode per-share returns; investors should wait for sustained free-cash-flow and margin expansion evidence rather than chase the current narrative-driven valuation.
Description
Caris Life Sciences is a US-based provider of molecular profiling services and related laboratory and data offerings to clinical and biopharmaceutical customers worldwide. The company supplies tissue- and blood-based tests for cancer treatment selection and supports drug development through laboratory execution, data products, and research services. Founded in 2008, Caris is headquartered in Irving, Texas.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 16 | Sep 23 | CAI | Caris Life Sciences, Inc. | Shares rose 37% over 21 trading days and broke above the prior $28.01 high on above-average volume. Revenue grew 45% to $263.7 million, 2026 guidance was raised, and the nationwide Caris Detect rollout adds a recent catalyst. | Closed | +12.2% |
| Aug 6 | Aug 13 | CAI | Caris Life Sciences, Inc. | Healthcare diagnostics catalyst with improving fundamentals: on 2026-08-05 Q2 revenue rose 45% YoY to $263.7M, full-year 2026 guidance was raised to $1.03B-$1.04B, and Caris Detect plus PTEN IHC testing expansion add product momentum. | Closed | +10.9% |
| Jun 26 | Jul 3 | CAI | Caris Life Sciences, Inc. | CAI has favorable near-term momentum and business catalysts: Q1 revenue rose 79% YoY to $216.2M, recent updates include product launch activity, MolDX approval, New York authorization filing, clinical validation progress, expanded oncology network, a $100M buyback authorization, and about 17.8% stock gain over 21 trading days. | Closed | -1.1% |
| Jun 18 | Jun 25 | CAI | Caris Life Sciences, Inc. | Constructive momentum plus catalysts: Q1 2026 revenue grew 79% YoY to $216.2M with positive free cash flow, liquidity is strong, and recent supports include a $100M buyback authorization and MolDX approval for Caris ChromoSeq. | Closed | +1.3% |
| Jun 9 | Jun 16 | CAI | Caris Life Sciences, Inc. | Positive catalyst stack with Q1 2026 revenue of $216.2M, up 79% YoY, plus Caris MI Clarity launch, Caris ChromoSeq launch and MolDX approval, NY State authorization filing for Caris Assure, and a $100M share repurchase program announced on 2026-06-08. | Closed | +6.0% |